These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 24488593)
1. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women. Del Mistro A; Frayle H; Ferro A; Callegaro S; Del Sole A; Stomeo A; Cirillo E; Fedato C; Pagni S; Barzon L; Zorzi M; J Med Screen; 2014 Mar; 21(1):30-7. PubMed ID: 24488593 [TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus test with cytology triage in organized screening for cervical cancer. Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407 [TBL] [Abstract][Full Text] [Related]
3. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. Veijalainen O; Kares S; Kotaniemi-Talonen L; Kujala P; Vuento R; Luukkaala T; Kholová I; Mäenpää J Acta Obstet Gynecol Scand; 2021 Mar; 100(3):403-409. PubMed ID: 33037625 [TBL] [Abstract][Full Text] [Related]
4. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222 [TBL] [Abstract][Full Text] [Related]
5. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922 [TBL] [Abstract][Full Text] [Related]
6. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804 [TBL] [Abstract][Full Text] [Related]
7. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain. Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073 [TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804 [TBL] [Abstract][Full Text] [Related]
9. Clinical performance of human papillomavirus based cervical cancer screening algorithm: The result of a large Danish implementation study. Lindquist S; Kjær SK; Frederiksen K; Ørnskov D; Petersen LK; Munk C; Waldstrøm M Acta Obstet Gynecol Scand; 2024 Sep; 103(9):1781-1788. PubMed ID: 39012789 [TBL] [Abstract][Full Text] [Related]
10. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women. Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849 [TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study. Agorastos T; Chatzistamatiou K; Moysiadis T; Kaufmann AM; Skenderi A; Lekka I; Koch I; Soutschek E; Boecher O; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Boschetti Gruetzmacher E; Tsertanidou A; Angelis L; Maglaveras N; Jansen-Duerr P Int J Cancer; 2017 Aug; 141(3):519-530. PubMed ID: 28470689 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778 [TBL] [Abstract][Full Text] [Related]
13. HPV testing with cytology triage for cervical cancer screening in routine practice. Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948 [TBL] [Abstract][Full Text] [Related]
14. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Gilham C; Sargent A; Kitchener HC; Peto J Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027 [TBL] [Abstract][Full Text] [Related]
15. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243 [TBL] [Abstract][Full Text] [Related]
16. Optimization of HPV-positive women triage with p16/Ki67 dual staining cytology in an organized cervical cancer screening program in the center region of Portugal. Sepodes B; Rebelo T; Santos F; Oliveira D; Catalão C; Águas F; Fernandes G Eur J Obstet Gynecol Reprod Biol; 2024 Nov; 302():111-115. PubMed ID: 39244854 [TBL] [Abstract][Full Text] [Related]
17. Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms. Ronco G; Zappa M; Franceschi S; Tunesi S; Caprioglio A; Confortini M; Del Mistro A; Carozzi F; Segnan N; Zorzi M; Giorgi-Rossi P; Eur J Cancer; 2016 Nov; 68():148-155. PubMed ID: 27755998 [TBL] [Abstract][Full Text] [Related]
18. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting. Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051 [TBL] [Abstract][Full Text] [Related]
19. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Wright TC; Stoler MH; Behrens CM; Sharma A; Zhang G; Wright TL Gynecol Oncol; 2015 Feb; 136(2):189-97. PubMed ID: 25579108 [TBL] [Abstract][Full Text] [Related]
20. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]